Compare Quest Diagnostics Inc (DGX) vs Oklo Inc (OKLO) Price & Performance

Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.

The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.

OKLO trades at $46.41, up 4.32% over 24 hours, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $77.07. The company reported its first revenue of $1.2 million in Q2 2026 but continues to post significant losses, with a net income margin of -12,625.54% in 2026. Recent milestones include achieving first criticality at its Groves isotope reactor, though cash burn remains high as it advances Aurora nuclear projects.

Outlook is speculative with high growth potential in nuclear energy infrastructure, but risks include persistent losses, execution challenges, and reliance on financing. Analyst sentiment is strongly bullish (76.9% buy ratings), yet investors must weigh the long-term payoff against near-term financial instability and market volatility.